Stay up-to-date on FSR’s latest activities and learn about the ways that FSR is driving progress and accelerating research towards a cure.
FSR launched the Ignore No More: ACTe Now! Campaign (Advance Clinical Trials for Equity in Sarcoidosis) to address the underrepresentation of Black Americans in clinical trials. As part of the campaign, FSR conducted the first of its kind, IRB-approved national patient survey for Black Americans to better understand the challenges and experiences Black Americans with sarcoidosis face as it pertains to clinical trials and their disease journeys. FSR also conducted a Key Opinion Leaders Thought Workshop (KOL) and Patient Focus Group to explore the findings in greater depth and to identify recommendations for how to improve clinical trial access and overall care of Black sarcoidosis patients.
Some recommendations that emerged include building a blueprint for clinical trial design that increases access and supports diversity, clinical trial navigation and support specifically targeted for Black patients, and educational toolkits to better educate patients and physicians about trial opportunities and engagement. Though this campaign was specific to Black Americans with sarcoidosis the learnings are relevant to improving access to clinical trials for all Black Americans.
Toolkits
White Papers
Annual Updates
Press Releases
FSR Blog
FSR Represented at ATS Public Advisory Roundtable
FSR Executive Director Ginger Spitzer attended the 2017 ATS Public Advisory Roundtable Planning Meeting on Nov 17-18 in Miami. Our membership in PAR allowsLearn More
Join Us in Jacksonville!
FSR will be hosting our seventh and final sarcoidosis patient education conference of the year in Jacksonville, Florida! Sarcoidosis Patient Education Conference November 11,Learn More
World Lung Day is September 25
The Forum of International Respiratory Societies (FIRS) has created a charter to recognize September 25th as World Lung Day. The purpose of the charter isLearn More
Study of ACZ885 (Canakinumab) in Patients with Pulmonary Sarcoidosis
The purpose of this study is to find out if the drug ACZ885 (Canakinumab) will improve lung function and also lower inflammation in patientsLearn More
Quick links
Check out these recent updates!